The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Quadrivalent Meningococcal Vaccine Market Research Report 2025

Global Quadrivalent Meningococcal Vaccine Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1739791

No of Pages : 90

Ask Your Query

Synopsis
The meningococcal quadrivalent vaccine protects against 4 types of meningococcus: types A, C, Y, and W.

Global Quadrivalent Meningococcal Vaccine market is projected to reach US$ 245.2 million in 2029, increasing from US$ 185 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Quadrivalent Meningococcal Vaccine market research.

Many countries have implemented meningococcal vaccination programs, especially targeting high-risk groups such as infants, adolescents and university students. Inclusion or recommendation of quadrivalent meningococcal vaccines in national immunization schedules can significantly influence the market demand.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Quadrivalent Meningococcal Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Sanofi-Pasteur
  • Walvax
  • Chengdu Kanghua Biological Products Co., Ltd.
  • Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
  • Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
  • Beijing Institute of Biological Products Co., Ltd.
  • CanSino Biological Co., Ltd.
  • Hualan Biological Vaccine Co., Ltd.
  • Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.

Segment by Type

  • Polysaccharide Vaccine
  • Conjugate Vaccine

Segment by Application

  • Hospital
  • Clinic

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Quadrivalent Meningococcal Vaccine report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Quadrivalent Meningococcal Vaccine Market Overview
1.1 Product Overview and Scope of Quadrivalent Meningococcal Vaccine
1.2 Quadrivalent Meningococcal Vaccine Segment by Type
1.2.1 Global Quadrivalent Meningococcal Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Polysaccharide Vaccine
1.2.3 Conjugate Vaccine
1.3 Quadrivalent Meningococcal Vaccine Segment by Application
1.3.1 Global Quadrivalent Meningococcal Vaccine Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Quadrivalent Meningococcal Vaccine Market Size Estimates and Forecasts
1.4.1 Global Quadrivalent Meningococcal Vaccine Revenue 2018-2029
1.4.2 Global Quadrivalent Meningococcal Vaccine Sales 2018-2029
1.4.3 Global Quadrivalent Meningococcal Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Quadrivalent Meningococcal Vaccine Market Competition by Manufacturers
2.1 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Quadrivalent Meningococcal Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Quadrivalent Meningococcal Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Product Type & Application
2.7 Quadrivalent Meningococcal Vaccine Market Competitive Situation and Trends
2.7.1 Quadrivalent Meningococcal Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Quadrivalent Meningococcal Vaccine Players Market Share by Revenue
2.7.3 Global Quadrivalent Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Quadrivalent Meningococcal Vaccine Retrospective Market Scenario by Region
3.1 Global Quadrivalent Meningococcal Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Quadrivalent Meningococcal Vaccine Global Quadrivalent Meningococcal Vaccine Sales by Region: 2018-2029
3.2.1 Global Quadrivalent Meningococcal Vaccine Sales by Region: 2018-2023
3.2.2 Global Quadrivalent Meningococcal Vaccine Sales by Region: 2024-2029
3.3 Global Quadrivalent Meningococcal Vaccine Global Quadrivalent Meningococcal Vaccine Revenue by Region: 2018-2029
3.3.1 Global Quadrivalent Meningococcal Vaccine Revenue by Region: 2018-2023
3.3.2 Global Quadrivalent Meningococcal Vaccine Revenue by Region: 2024-2029
3.4 North America Quadrivalent Meningococcal Vaccine Market Facts & Figures by Country
3.4.1 North America Quadrivalent Meningococcal Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Quadrivalent Meningococcal Vaccine Sales by Country (2018-2029)
3.4.3 North America Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Quadrivalent Meningococcal Vaccine Market Facts & Figures by Country
3.5.1 Europe Quadrivalent Meningococcal Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2029)
3.5.3 Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Quadrivalent Meningococcal Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Quadrivalent Meningococcal Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Quadrivalent Meningococcal Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Quadrivalent Meningococcal Vaccine Market Facts & Figures by Country
3.7.1 Latin America Quadrivalent Meningococcal Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Quadrivalent Meningococcal Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Quadrivalent Meningococcal Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Quadrivalent Meningococcal Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Quadrivalent Meningococcal Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Quadrivalent Meningococcal Vaccine Sales by Type (2018-2029)
4.1.1 Global Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023)
4.1.2 Global Quadrivalent Meningococcal Vaccine Sales by Type (2024-2029)
4.1.3 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2029)
4.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023)
4.2.2 Global Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2029)
4.2.3 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Quadrivalent Meningococcal Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Quadrivalent Meningococcal Vaccine Sales by Application (2018-2029)
5.1.1 Global Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023)
5.1.2 Global Quadrivalent Meningococcal Vaccine Sales by Application (2024-2029)
5.1.3 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2029)
5.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023)
5.2.2 Global Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2029)
5.2.3 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Quadrivalent Meningococcal Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Sanofi-Pasteur
6.1.1 Sanofi-Pasteur Corporation Information
6.1.2 Sanofi-Pasteur Description and Business Overview
6.1.3 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Portfolio
6.1.5 Sanofi-Pasteur Recent Developments/Updates
6.2 Walvax
6.2.1 Walvax Corporation Information
6.2.2 Walvax Description and Business Overview
6.2.3 Walvax Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Walvax Quadrivalent Meningococcal Vaccine Product Portfolio
6.2.5 Walvax Recent Developments/Updates
6.3 Chengdu Kanghua Biological Products Co., Ltd.
6.3.1 Chengdu Kanghua Biological Products Co., Ltd. Corporation Information
6.3.2 Chengdu Kanghua Biological Products Co., Ltd. Description and Business Overview
6.3.3 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.3.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments/Updates
6.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
6.4.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Corporation Information
6.4.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Description and Business Overview
6.4.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.4.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments/Updates
6.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
6.5.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Corporation Information
6.5.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Description and Business Overview
6.5.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.5.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments/Updates
6.6 Beijing Institute of Biological Products Co., Ltd.
6.6.1 Beijing Institute of Biological Products Co., Ltd. Corporation Information
6.6.2 Beijing Institute of Biological Products Co., Ltd. Description and Business Overview
6.6.3 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.6.5 Beijing Institute of Biological Products Co., Ltd. Recent Developments/Updates
6.7 CanSino Biological Co., Ltd.
6.6.1 CanSino Biological Co., Ltd. Corporation Information
6.6.2 CanSino Biological Co., Ltd. Description and Business Overview
6.6.3 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.7.5 CanSino Biological Co., Ltd. Recent Developments/Updates
6.8 Hualan Biological Vaccine Co., Ltd.
6.8.1 Hualan Biological Vaccine Co., Ltd. Corporation Information
6.8.2 Hualan Biological Vaccine Co., Ltd. Description and Business Overview
6.8.3 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.8.5 Hualan Biological Vaccine Co., Ltd. Recent Developments/Updates
6.9 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
6.9.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Corporation Information
6.9.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Description and Business Overview
6.9.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Portfolio
6.9.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Quadrivalent Meningococcal Vaccine Industry Chain Analysis
7.2 Quadrivalent Meningococcal Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Quadrivalent Meningococcal Vaccine Production Mode & Process
7.4 Quadrivalent Meningococcal Vaccine Sales and Marketing
7.4.1 Quadrivalent Meningococcal Vaccine Sales Channels
7.4.2 Quadrivalent Meningococcal Vaccine Distributors
7.5 Quadrivalent Meningococcal Vaccine Customers
8 Quadrivalent Meningococcal Vaccine Market Dynamics
8.1 Quadrivalent Meningococcal Vaccine Industry Trends
8.2 Quadrivalent Meningococcal Vaccine Market Drivers
8.3 Quadrivalent Meningococcal Vaccine Market Challenges
8.4 Quadrivalent Meningococcal Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock